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microRNAs (miRNAs) have been identiﬁed as a ﬁne-tuner in a wide array of biological
processes, including development, organogenesis, metabolism, and homeostasis. Dereg-
ulation of miRNAs causes diseases, especially cancer. This occurs through a variety of
mechanisms, such as genetic alterations, epigenetic regulation, or altered expression of
transcription factors, which target miRNAs. Recently, it was discovered that extracellular
miRNAs circulate in the blood of both healthy and diseased patients. Since RNase is abun-
dant in the bloodstream, most of the secretory miRNAs are contained in apoptotic bodies,
microvesicles, and exosomes or bound to the RNA-binding proteins. However, the secre-
torymechanism and biological function, as well as the signiﬁcance of extracellular miRNAs,
remain largely unclear. In this article, we summarize the latest and most signiﬁcant discov-
eries in recent peer-reviewed research on secretory miRNA involvement in many aspects
of physiological and pathological conditions, with a special focus on cancer. In addition, we
discuss a new aspect of cancer research that is revealed by the emergence of “secretory
miRNA.”
Keywords: secretory microRNA, microRNA, exosome, cell–cell communication, cancer
INTRODUCTION
microRNAs (miRNAs) are small non-coding RNA that repress a
wide variety of target genes expression at the post-transcriptional
level by sequence-speciﬁc base pairing to the 3′ untranslated region
of multiple target mRNAs. They are conserved through species,
and forman important class of regulators that participate inmulti-
ple biological phenomena, including development, organogenesis,
and homeostasis. Because of their ability to bind to many tar-
get mRNAs (Kwak et al., 2011), once their expression is altered,
disease could occur through the deregulation of their target gene
networks, particularly that leading to cancer. For this reason,many
recent studies have focused on the development of novel diagno-
sis and therapeutics in the ﬁeld of oncology. Current studies have
revealed that miRNAs are secreted outside of the cells, and their
biological signiﬁcance is beginning to be recognized (Zernecke
et al., 2009; Kosaka et al., 2010b; Pegtel et al., 2010). This article is
a summary of the latest and most signiﬁcant ﬁndings of original
studies on the involvement of secretory miRNAs in cancer, with a
special focus on the potential of secretory miRNAs as a humoral
factor for cancer biology.
RNA IS NOT ONLY THE MEDIATOR IN THE CENTRAL DOGMA
BUT ALSO A SECRETORY FUNCTIONAL MOLECULE
Before Watson and Crick (1953) described the double-helical
structure of the DNA molecule, Mandel and Metais (1947) had
found that DNA is present in plasma and serum in 1947. They
showed the presence of nucleic acids in healthy subjects as well as
in ill patients. After that, many researchers have tried to examine
the circulating nucleic acid to develop them as a potential bio-
marker, especially in the research ﬁeld of cancer (Fleischhacker
and Schmidt, 2007). It is now well documented that RNA can also
be detected in plasma, serum, and other body ﬂuids as well as
from cell-free supernatants of in vitro cultivated cells. One of the
ﬁrst papers demonstrating the presence of extracellular RNA was
published by Stroun et al. (1978). They reported the presence of
an RNA form in a nucleoprotein complex spontaneously released
from human blood lymphocytes and frog cell systems from auri-
cle cultures. They also showed that the RNA from this complex
has a stimulating effect on DNA synthesis in vitro, suggesting the
function of secretory RNA in recipient cells.
Meanwhile, the uptake of RNA by recipient cells was also
observed. More than 40 years ago, RNAs were reported to be read-
ily taken up by ascites tumor cells (Galand and Ledoux, 1966). In
addition, during a study of co-cultured cells that were previously
incubated with or without tantalum particles, intact labeled RNA
was found to be transferred into the non-labeled recipient cells
from labeled donor cells (Kolodny, 1971). Namely, cell–cell com-
munication was mediated not only by proteins, such as cytokines,
chemokines, and hormones, but also by secretory RNA.
Given that the concentration of RNA-degrading enzymes,
RNase, is high in normal people and even higher in cancer patients
(Reddi and Holland, 1976; Tsui et al., 2002) and that RNase is
extremely stable, it was reasoned that the RNA released from the
cells into the extracellular space must be complexed and in a form
that is resistant against RNases. The ﬁrst study of associating circu-
latingRNA,as RNA–proteolipid complexes, in serumwas reported
in 1987 (Wieczorek et al., 1987). This study reported a relationship
between the presence of RNA–proteolipid complexes and tumor
mass/response to therapy. These complexes disappeared ∼48 h
after tumor removal and were undetected in benign disorders.
Another study demonstrated that the release of a macromolecu-
lar substance containing 32P and 3H was found when prelabeled
www.frontiersin.org January 2012 | Volume 2 | Article 97 | 1
Kosaka and Ochiya Secretory microRNA in cancer research
Chinese hamster ovary cells were treatedwith trypsin under condi-
tions in which cells remain fully viable (Rieber and Bacalao, 1974).
In contrast, a ribonuclease treatment affected neither the 32P nor
the 3H radioactivity. The authors concluded from these experi-
ments that RNA together with glycoproteins is released from the
external cell surface.
FUNCTIONAL IMPORTANCE OF SECRETORY miRNA IN
VARIOUS KINDS OF LIFE PHENOMENA
miRNAs, a class of post-transcriptional gene expression regula-
tors, play critical roles in various kinds of biological phenomena,
including development, organogenesis, and homeostasis. Dysreg-
ulation of miRNA leads to cancer development and progression
and has different expression proﬁles in normal tissues and can-
cers (Garzon et al., 2010). For this reason, miRNAs have been
investigated for their potential use in the diagnosis, prognosis,
and treatment of cancer. miRNAs have recently been detected in
human body ﬂuids, including peripheral blood plasma as extra-
cellular nuclease-resistant entities (Kosaka et al., 2010a). Reports
in two landmark papers noted that not only mRNAs but also miR-
NAs were secreted outside of the cells and circulated in human
body ﬂuid (Chim et al., 2008; Lawrie et al., 2008). Chim et al.
(2008) reported the existence of placental miRNAs in maternal
plasma. Interestingly, they showed that the four most abundant
placental miRNAs (miR-141, miR-149, miR-299-5p, and miR-
135b) were detectable in maternal plasma during pregnancy and
showed reduced detection rates in post-delivery plasma. Further-
more, Lawrie et al. (2008) investigated whether miRNAs have
diagnostic utility by comparing the levels of tumor-associated
miR-155, miR-210, and miR-21 in serum from diffuse large B-
cell lymphoma patients with healthy controls and showed that the
levels were higher in patients than in control sera. These obser-
vations support the idea that circulating miRNAs can be used as
biomarkers to monitor an individual’s health. In addition, these
reports also suggest the possibility that secretory miRNA must be
contained in or attached to something that could protect RNA
from RNase-mediated degradation.
One breakthrough about circulating RNA was the discovery
of mRNA and miRNA in exosomes (Valadi et al., 2007). Valadi
et al. (2007) showed that mouse and human mast cell-derived
exosomes, which are vesicles of endocytic origin released by many
kinds of cells that canmediate communication between cells, con-
tain RNA andmiRNA. The RNA frommast cell exosomes is trans-
ferable to other mouse and human mast cells. After the transfer of
mouse exosomal RNA to human mast cells, new mouse proteins
were found in the recipient human cells, indicating that trans-
ferred exosomal mRNA can be translated after entering another
cell. Observations from these three reports indicated one impor-
tant fact, namely, that miRNA could be existent in the outer space
of the cells, where the RNase is present, and could be functional in
this new location.
After the discovery of miRNA in exosome, many researchers
attempted to identify the function of secretorymiRNAbecause the
report from Valadi et al. (2007) had not clariﬁed it in the exoso-
mal miRNA in recipient cells. One of the earliest studies to prove
the function of secretory miRNA was revealed by an apoptotic
body (Zernecke et al., 2009). They demonstrated that CXCL12
production was mediated by miR-126, which was enriched in
apoptotic bodies and repressed the function of the regulator of
G protein signaling 16. This enabled CXCR4 to trigger an autoreg-
ulatory feedback loop that increased the production of CXCL12,
leading to the recruitment of progenitor cells. This study strongly
indicated the importance of a “dying message” for the regulat-
ing homeostasis of a healthy status and highlights the functions
of miRNAs in health and disease that may extend to the recruit-
ment of progenitor cells during other forms of tissue repair or
homeostasis.
After the study of miRNA in apoptotic bodies, three reports
showed the function and transfer of secretory miRNAs contained
inside the exosome. Pegtel et al. (2010) showed that mature EBV-
encodedmiRNAs are secreted byEBV-infectedB cells through exo-
somes. These EBV-miRNAs repress the EBV target immunoregu-
latory genes, and these target genes are down-regulated in pri-
mary EBV-associated lymphomas. Interestingly, using peripheral
blood mononuclear cells from patients with an increased EBV
load, these researchers also showed that, although EBV DNA is
restricted to the circulating B-cell population, EBV BART miR-
NAs are present in both B-cell and non-B-cell fractions, suggestive
of miRNA transfer in vivo. Zhang et al. (2010) reported that
miR-150 is contained inside the exosomes and is secreted from
a cultured human monocyte/macrophage cell line and that this
exosome delivers miR-150 into human microvascular endothelial
cells. Then, elevated exogenousmiR-150 effectively reduced c-Myb
expression and enhanced cell migration in human microvascular
endothelial cells. Our group also demonstrated that a secreted
tumor-suppressive miRNA, which is miR-146a down-regulated in
prostate cancer, was transported to cancer cells and exerted gene
silencing in the recipient prostate cancer cells through the suppres-
sion of its target gene, thereby leading to cell growth inhibition
(Kosaka et al., 2010b). This suggested that secreted miRNA could
function as a cell–cell communication tool between the cancer
cells and their microenvironmental cells.
These three reports clariﬁed a variety of physiological and
pathological phenomena, including virus infection, vascular dis-
ease, and cancer. The variety of research ﬁelds highlights the
importance of secretory miRNAs in phenomena vital to life.
Indeed, recent reports have pointed to various functions of secre-
tory miRNA in many aspects of life, such as cellular commu-
nication involving antigen-dependent, unidirectional intercellu-
lar transfer of miRNAs by exosomes during immune synapsis
(Mittelbrunn et al., 2011), nasopharyngeal carcinoma-mediated
transfer of EBV-encoded BART miRNA (Gourzones et al., 2010),
hepatocellular carcinoma (Kogure et al., 2011), and cardiovas-
cular diseases (Kuwabara et al., 2011). These reports mainly
described the importance of exosomes as an miRNA carrier; how-
ever, it is not always the exosome that is important in secretory
miRNA-mediated cell–cell communication.
High-density lipoprotein (HDL) transports endogenous miR-
NAs and delivers them to recipient cells with functional targeting
capabilities (Vickers et al., 2011). The humanHDL-miRNA proﬁle
of normal subjects is signiﬁcantly different from that of famil-
ial hypercholesterolemia subjects. Interestingly, a recent report
showed that the mechanism of horizontal transfer of miRNAs
is not only dependent on vesicle transfer, such as exosomes, but
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also intercellular connection tools, such as gap junction and RNA-
binding protein. Lim et al. (2011) clariﬁed that miRNA was
transmitted from bone marrow stroma to breast cancer cells via
gap junctions and exosomes in tumor cell quiescence. Arroyo
et al. (2011) employed a technique, differential centrifugation and
size-exclusion chromatography, to characterize circulatingmiRNA
complexes in human plasma and serum and found that themajor-
ity of circulating miRNAs cofractionated with Argonaute2 (Ago2,
the key effector protein of miRNA-mediated silencing) protein
complexes rather than within vesicles. This study was also con-
ﬁrmed by other groups which have shown Ago2 (Turchinovich
et al., 2011) or nucleophosmin 1 as secretory miRNA carri-
ers (Wang et al., 2010). Further biological studies are required
to understand the function of miRNAs secreted with an RNA-
binding protein, such as Ago2 or nucleophosmin 1, in a variety of
research ﬁelds.
To certify the signiﬁcance of secretory miRNAs in variety of life
phenomena, it is also essential to understand the secretion mech-
anism of miRNA from cells. Previously, we found in HEK293 and
COS-7 cells that the secretion of miRNAs was regulated by neu-
tral sphingomyelinase 2 (nSMase 2; Kosaka et al., 2010b), which
is the catalytic enzyme of ceramide biosynthesis and is known
as an exosome regulatory protein (Trajkovic et al., 2008). The
decreased activity of nSMase 2with a chemical inhibitor,GW4869,
and a speciﬁc siRNA resulted in the reduced secretion of miR-
NAs. Complementarily, overexpression of nSMase 2 increased the
extracellular amounts of miRNAs. This observation was also con-
ﬁrmed using other cells including T-cells (Mittelbrunn et al., 2011)
and hepatocellular carcinoma cells (Kogure et al., 2011). Contrary
to our results, inhibition of nSMase 2 signiﬁcantly increased the
amount of miRNAs exported to HDL from macrophages (Vickers
et al., 2011).
It remains necessary to elucidate howmiRNA is sorted into exo-
somes or other vesicles, such as microvesicles. Microvesicles, also
knownasmicroparticles or shedding vesicles, represent a heteroge-
neous population of vesicles with a diameter of 100–1000 nm that
are released by budding of the plasma (Muralidharan-Chari et al.,
2010). It has been shown that microvesicles isolated from embry-
onic stem cells increase pluripotency of hematopoietic stem cells
after horizontal transfer of embryonic stem cell-derived mRNA.
Although the functions of microvesicles were recently elucidated,
unlike exosome, not only the function but also the sorting mech-
anisms of miRNAs into microvesicles have not been clariﬁed yet.
Furthermore, it has not been shown yet what kind of protein bind
to miRNAs in the vesicles such as exosomes, microvesicles, and
apoptotic bodies, althoughArroyo et al. (2011) clearly showed that
circulating Ago2-binding miRNAs were not contained inside vesi-
cles. Gibbings et al. (2009) detected some AGO2 in the puriﬁed
exosomes, albeit less than in whole-cell lysates, on the contrary,
GW182, which required for miRNA function through its bind-
ing to AGO2, was dramatically enriched in exosomes. Detecting
the proteins, which bind to miRNAs in vesicles, might lead to
revealing the sorting mechanism of miRNAs in vesicles. Clarify-
ing the details of the molecular mechanisms of secretory miRNA,
such as the manner of cell–cell transfer or secretion mechanisms,
will help us understand a variety of diseases, especially cancer
(Figure 1).
SECRETORY miRNA AS A HUMORAL FACTOR IN CANCER
CELLS
As shown in this report, secretory miRNAs are functional mole-
cules thatmodulatemany aspects of the biological process. In addi-
tion, destruction of the secretion of miRNA from cells might lead
to disease, such as cardiovascular diseases, virus infections, deteri-
oration of the immune system, and cancer. From the ﬁeld of cancer
research, we would like to propose two hypotheses regarding
secretory miRNA-mediated cancer progression (Figure 2).
One is the function of secretory miRNA in a metastatic niche
(Figure 2A). As already shown in several reports, various types
of the cells have been shown to have the capability to take up
exosomes. The tumormicroenvironment is a complex tissue com-
prising variable numbers of tumor cells, epithelial cells which
originated cancer cells, ﬁbroblasts, endothelial cells, and inﬁl-
trating leukocytes. Recent reports have explained the mechanism
of controlling the cancer cell-mediated phenotypical change of
microenvironmental cells through cytokines (Hanahan andWein-
berg, 2011). Cytokines are considered as keymolecules controlling
autocrine or paracrine communications within and between these
individual cell types. However, considering the existence of secre-
tory miRNA within these environments, their inﬂuence to the
cancer niche should be reconsidered. An exosome contains nearly
300 proteins (Atay et al., 2011) with the potential to modulate the
state of microenvironment cells. In addition, miRNAs are known
to regulate hundreds of target mRNA expressions. Thus, not only
exosomalmiRNAs but also other types of secretorymiRNAs could
control the state of cellular phenotypes to the beneﬁt of cancer cells
within their niche.
Another hypothesis deals with the function of secretory miR-
NAs in distant organs (Figure 2B). Recently, Hood et al. (2011)
provided evidence of exosome-mediated conditioning of lymph
nodes and deﬁned microanatomic responses that enable the
metastasis of melanoma cells. Homing of melanoma exosomes to
sentinel lymphnodes imposes synchronizedmolecular signals that
affect melanoma cell recruitment, extracellular matrix deposition,
and vascular proliferation in the lymph nodes. They showed the
physiological importance of exosomes for distal metastasis; how-
ever, they have not provided evidence of themolecules species that
take part in themodulation of the distal site of metastasis. To reveal
the exact function of miRNA targeting sites that are distant from
the primary organ, we should identify the molecular mechanisms
of the tropism of secretory miRNA transported by carriers.
SECRETORY miRNA AS A HUMORAL FACTOR IN ORGANISMS
In this study, systemic transfer of miRNAs has been introduced.
However, an active mechanism for the transport of double strand
RNA (dsRNA) across tissues and cellular boundaries was found
in other organisms, such as nematode and plant. Transmembrane
channel-forming protein SID-1 has been shown tomediate passive
cellular uptake and cell-to-cell distribution of dsRNA in the nema-
tode C. elegans (Feinberg and Hunter, 2003). In addition, recent
report showed that mammalian SID-1 homolog localized to the
cellmembrane of human cells enhances their uptake of small inter-
fering RNA, resulting in increased siRNA-mediated gene silencing
efﬁcacy (Duxbury et al., 2005). Furthermore, althoughRNAmole-
cules have been implicated in systemic cell-to-cell communication
www.frontiersin.org January 2012 | Volume 2 | Article 97 | 3
Kosaka and Ochiya Secretory microRNA in cancer research
FIGURE 1 | Unveiling the mechanisms and roles of secretory miRNAs in
both physiological and pathological conditions is essential for the
development of novel diagnostic methods and therapeutics to treat
various human diseases. In the physiological condition, secretory miRNAs
may maintain the homeostasis of organs and tissues via diverse types of
miRNA carriers (A). However, this state may be destroyed by the change of
phenotype in donor cells or recipient cells (B). From the viewpoint of donor
cells, changes in the phenotype of donor cells may lead to the alteration of
miRNA species with carriers (C). Furthermore, the quantity of secretory
miRNA uptake by recipient cells may change in this situation (D). It is
necessary to understand these abnormal changes of molecular mechanisms
for the development of a therapy against “secretory miRNAs-mediated
diseases.” In addition, it is possible that the amount of secretory miRNAs
changes in this situation through the abnormal regulation of carrier production
(E). Understanding these changes may lead to the exploitation of a diagnosis
marker for “secretory miRNAs-mediated diseases.”
in plants (Chitwood and Timmermans, 2010), recent studies have
shown that miRNAs are mobile signals that control gene expres-
sion during plant development (Dunoyer et al., 2010;Molnar et al.,
2010), suggesting that the transfer of RNA is found globally in
organisms.
Surprisingly, Zhang et al. (2011) reported that exogenous plant
miRNAs are present in the sera and tissues of various animals
and that these exogenous plant miRNAs are primarily acquired
orally, through food intake. Rice abundant miRNA, miR-168a,
is one of the most highly enriched exogenous plant miRNAs in
the sera of Chinese subjects. Furthermore, they also found that
MIR168a could bind to the human/mouse low-density lipoprotein
receptor adapter protein 1 (LDLRAP1) mRNA, inhibit LDLRAP1
expression in liver, and consequently decrease LDL removal from
mouse plasma. This study prompted the idea that miRNAs could
regulate the gene expression across the kingdom. In addition,
one of the important point of this study is that identiﬁcation
of plant miRNAs in human peripheral blood was performed by
Solexa sequencing. High-throughput transcriptome analysis by
Next Generation Sequencing, speciﬁcally RNAseq, is currently
widely available. As shown in the case of rice miRNAs, these tech-
niques may help answer the question about the novel small RNAs
recently discovered to be secreted.
FUTURE DIRECTIONS FOR RESEARCH ON SECRETORY RNAs
In this review, we summarized the recent ﬁndings of secretory
miRNAs. The research ﬁeld of secretory miRNAs has just begun.
To use the knowledge of secretory miRNAs for human health, we
should unveil the mystery of secretory RNA as follows.
First, we need to know the all kinds of secretory RNA species.
Interestingly, Dinger et al. (2008) independently analyzed the
microarray dataset from Valadi et al.’s (2007) study and found
that many longer non-coding RNAs (ncRNAs) were also present
in exosomes, including a number of ncRNAs associated with
important genes and several known ncRNAs, such as Copg2as
and Nespas, in mast cell-derived exosomes. This question seems
quite easy to obtain the answer. As we already mentioned above,
recent development of next generation sequencing technologies
has been developed. This means that we can directly recognize the
nucleic acids that can exist outer space of the cells.
Second, secretory machinery of miRNAs and other types of
RNA should be clariﬁed. As described in this paper, we recently
detected the part of miRNAs secretion mechanism mediated by
exosome (Kosaka et al., 2010b). Analyzing the secretion mecha-
nism of various kinds of RNAs and sorting mechanism of miRNA
into the vesicles leads the development of novel nucleic acids based
medicine.
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FIGURE 2 |Two proposed hypotheses regarding secretory
miRNA-mediated cancer progression. (A) Secretory miRNAs mediate
the modulation of microenvironmental cells. Secretory miRNAs from
cancer cells control the behavior of microenvironmental cells for their own
beneﬁt. (B) Secretory miRNAs could be functional molecules in a distant
organ.
Last point is to know the function of secretory miRNAs in
more detail, such as physiological conditions and pathological
conditions. Reports on the function of secretory miRNAs in phys-
iological conditions, such as embryogenesis, organogenesis, and
maintaining tissue and organ homeostasis, are not available. In
addition, to know the function of secretory miRNAs, we need
to know the incorporation mechanism of miRNAs. Although
SID-1 found in C. elegans is good example of secretory miRNA
transport mechanism, the other machinery might exist in ver-
tebrates. Indeed, both transporter-dependent (SID-1 dependent)
and transporter-independent (SID-1 independent) dsRNA export
takes place from C. elegans cells (Jose et al., 2009). Furthermore,
as shown previously, miRNA from plant was detected in human
circulating peripheral blood, and the function of plant derived
miRNA was documented by the authors, suggesting that other
types of small RNA fromother speciesmight contribute to the reg-
ulatingof physiological or pathological situation.BecausemiRNAs
act asmulti-functional molecules via the binding to sequence sim-
ilarities and regulate various life phenomena, secretory miRNAs
might be a humoral factor that exerts its inﬂuence in distant
organs, similarly to hormones. Clarifying the species,mechanisms
and roles of secretory miRNA, and other secretory ncRNAs in
both pathological and physiological conditions would unveil the
mystery of “secretory miRNAs-mediated disease” (Figure 1).
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